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Although cultured myoblast transplantation has been ex-
tensively studied as a gene complementation approach to
muscular dystrophy treatment, clinical success has still been
limited. The inability to adequately isolate and purify myo-
blasts presents a major limitation to the production of sufficient
myoblasts for engrafting purposes. This study attempted to
purify myoblasts from primary culture by magnetic-activated
cell sorting (MACS), complement-mediated cytotoxicity, and
a preplating technique. As a result of positive myoblasts
selection by MACS, the average percentage of myoblasts in
mixed culture was increased from 30.0% to 41.7%. We
observed both myoblast lysis and fibroblast lysis after comple-
ment-mediated cytotoxicity. Enrichment of myoblasts in mixed
culture was found to increase to 83.1% by using the preplating
technique. In addition, higher purification (92.8%) was
achieved by following the preplating technique with MACS.
Thus, preplating in combination with magnetic-activated cell
sorting allows for a rapid and effective isolation of myoblasts
from human muscle tissue.
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INTRODUCTION
Duchenne muscular dystrophy (DMD) is a
severe X-linked neuromuscular disease that affects
approximately 1/3500 live male births, regardless
of ethnicity. This condition is known to be caused
by a mutation in the gene that encodes the muscle
protein dystrophin.
1-7 There is currently no cure
for DMD, although intensive research on experi-
mental treatments is underway. One experimental
treatment is based on myoblast transfer. This
approach has a number of limitations including a
low rate of spread, poor survival of injected myo-
blasts and insufficient donor myoblasts. Further-
more, the production of myoblasts for engrafting
purposes is limited by problems in myoblast
isolation and purification and in the maintenance
of a satellite cell state (i.e., undifferentiated cells)
before transplantation.
5,7-10 Human myoblasts can
be isolated from muscle biopsy, but these are
easily contaminated by fibroblasts or other non-
myogenic cells in vitro.
Several myoblast purification procedures have
been reported. Percoll density centrifugation,
selective adhesion and chemical use of fibroblast
growth inhibitors have all been used for myogenic
cell separation, although the yield of myoblasts
from primary culture is limited.
11-13 To date, the
methods used to improve yields include the
incorporation of muscle-specific antibody in
fluorescence-activated cell sorting and size separa-
tion-based sorting by flow cytometry.
14-16 These
methods, however, require special equipment and
techniques.
This study attempted to purify myoblasts from
primary culture by magnetic-activated cell sorting
(MACS), complement-mediated cytotoxicity, pre-
plating and combined preplating and MACS. In
addition, we compared the results with untreated
A Comparative Study of Magnetic-Activated Cell Sorting,
Cytotoxicity and Preplating for the Purification of Human
Myoblasts
Yoon Ghil Park, Jae Ho Moon, and Jin Kim
Department of Rehabilitation Medicine and Rehabilitation Institute of Muscular Disease, Yonsei University College of Medicine,
Seoul, Korea.
Received May 6, 2005
Accepted October 10, 2005
This work was supported by a Korea Research Foundation Grant
(KRF-2002-003-E00129).
Reprint address: requests to Dr. Yoon Ghil Park, Department
of Rehabilitation Medicine, Yongdong Severance Hospital, Yonsei
University College, 146-92 Dogok-dong, Gangnam-gu, Seoul 135-
270, Korea. Tel: 82-2-2019-3493, Fax: 82-2-3463-7585, E-mail:
drtlc@yumc.yonsei.ac.kr
Original ArticleYoon Ghil Park, et al.
Yonsei Med J Vol. 47, No. 2, 2006
cells and report upon the efficiency of each of
these methods in purifying primary myoblasts.
Finally, we observed the differentiation of the




Human skeletal muscle samples were obtained
from volunteers with informed consent and
following the regulations of the Ethics Committee
of Yongdong Severance Hospital, Yonsei Univer-
sity College of Medicine. All patients received a
physical examination, blood screening for possible
neuromuscular disorders and provided a medical
history.
Preparation of primary culture
Primary muscle cells were removed from the
vastus lateralis muscles as previously described.
17,18 The muscle mass was rinsed in phosphate
buffered saline (PBS; GIBCO BRL, Grand Island,
NY, USA) and minced into a coarse slurry using
blades. Cells were enzymatically dissociated by
adding 0.2% collagenase type XI (Sigma, St. Louis,
MO, USA) for 1 h at 37 and 5% CO2. The iso-
lated cells were then suspended in Dulbecco's
modified Eagle's medium with 20% fetal bovine
serum (FBS-DMEM; containing 1% gentamycin;
GIBCO BRL). The cells were then plated in
gelatin-coated flasks at 1 × 10
6 cells/mL and
incubated at 37 and 5% CO2 until 50% con-
fluent. The growth medium was replaced twice a
week. When cells reached 50% confluence, the
medium was discharged and 0.05% trypsin-0.53
mM EDTA (Life Technologies, Rockville, MD,
USA) was added. The cells were harvested by
centrifugation at 1100 rpm for 10 min, and either
subcultured or used to evaluate the isolation
methods.
Magnetic-activated cell sorting (MACS)
Primary culture cells were rinsed with PBS after
detaching and centrifuged at 1100 rpm for 10 min.
Pelleted cells were resuspended in PBS with a
1:100 dilution of the myoblast-specific monoclonal
antibody, 5.1H11 (Developmental Studies Hybri-
doma Bank, Iowa University, Iowa City, IA, USA).
The cell-antibody complex was incubated at room
temperature for 30 min and rinsed twice with
PBS. This step was followed by a 15 min incuba-
tion at 6-12 with a 1:5 dilution of goat anti-
mouse IgG microbeads (Miltenyl Biotec GmbH,
Bergisch Gladbach, Germany). The mixture was
subjected to a magnetic field, and myoblasts
adhered to IgG microbeads were separated using
a MiniMACS separation system (Miltenyl Biotec
GmbH).
Complement-mediated cytotoxicity
The primary culture cells were detached from
the flask with 0.05% trypsin-0.53 mM EDTA, as
described above. The cells were reacted with 1:800
IgM monoclonal antibody 1B10 (Sigma) at 37
and 5% CO2 for 50 min. The cells were then rinsed
with PBS and incubated at 37 and 5% CO2 in
12.5% young rabbit serum (Sigma) and 20% FBS-
DMEM for 45 min.
Preplating
The preplating technique was performed using
previously described protocols with slight modifi-
cation.
17,18 Briefly, the primary culture cells were
detached and then preplated in a gelatin-coated
flask. After 5-10 min of incubation at 37 and 5%
CO2, the supernatant was withdrawn from the
flask, and cells were replated in a fresh gelatin-
coated flask. Because of different adherence rates,
mainly fibroblasts had adhered to the new flask
at 50% total adherence.
17-19 Serial replatings of the
fibroblast-depleted supernatant were then per-
formed in gelatin-coated flasks. After 5 serial
platings, the culture was enriched with small,
round myogenic cells (pp5). Preplate 1 (pp1) was
the population of myoblasts that adhered in the
first 10 min, and were incubated for 3-4 days until
70% confluent.
Immunohistochemistry for desmin
Myoblasts were determined by desminPurification of Human Myoblasts
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staining. Cultured cells mounted on saline-coated
slides were air-dried at room temperature for 10
minutes. Endogenous peroxidase activity was
blocked by incubating the cells on slides in 3%
H2O2 for 10 minutes and rinsing with tris-
buffered saline (TBS; DAKO Co., Carpinteria,
CA, USA). The cells were then incubated for one
hour at room temperature with monoclonal
mouse primary antibodies against desmin
(DAKO). After rinsing with TBS, the cells were
incubated with biotin-labeled secondary anti-
bodies using a labeled streptavidin-biotin (LSAB)
kit (DAKO) at room temperature for 15 min.
After rinsing with TBS, the cells were incubated
with streptavidin peroxidase at room tempera-
ture for 15 minutes, and rinsed with TBS. The
cells were developed using 3-amino-9-ethyl car-
bazole (AEC), rinsed with distilled water and
counterstained with hematoxylin. Cell density
was determined by counting the number of
desmin positive cells per microscope field (×
100) in 10 random fields.
Differentiation
Myoblasts treated with MACS and/or by
preplating were transferred to 1% FBS-DMEM
after the treatment(s) had been completed. The
myoblasts were incubated at 37 and 5% CO2.
Differentiation into myotubes was observed under
a phase-contrast microscope.
Statistical analysis
Each experiment was repeated three times to
reduce bias, and results expressed are the
medians. The Mann-Whitney test for equal pro-
portions was used in SPSS for Windows 10.0
(SPSS Inc. Chicago, IL, USA) to evaluate statisti-
cally significant differences (p < 0.05) between
"before" and "after" treatments.
RESULTS
Magnetic-activated cell sorting (MACS)
Beads were coated with goat anti-mouse IgG
which recognized 5.1H11, a human myoblast-
specific antibody. Bridges of antibodies allowed
target cells to attach to the magnetic beads, which
were isolated using a magnetic collector device,
MiniMACS. As a result, positive selection of
myoblasts by MACS increased the percentage of
myoblasts in mixed culture from 30.0% to 41.7%
(Fig. 1).
Complement-mediated cytotoxicity
Complement-mediated cytotoxicity did not sig-
nificantly increase the number of myoblasts in
mixed culture (Fig. 1). Furthermore, myoblasts
were lysed along with fibroblasts. It would appear
that 1B10, a monoclonal anti-fibroblast antibody,
cross-reacted with myoblasts.
Preplating
The preplate technique is based on the differen-
tial adherence characteristics of primary culture
cells to a gelatin-coated surface, and it signifi-
cantly enriches myoblasts. As shown in Fig. 2, the
fraction of desmin positive cells increased from
primary culture to pp5, in which 83.1% of cells
expressed desmin, as compared to 21.3% in the
primary culture. In order to obtain yet higher
yields of myoblasts, preplated cells (pp5) were
subjected to MACS, whereupon myoblasts in-
creased from 76.4% to 92.8% (Fig. 1).
Fig. 1. Percentage increase of myoblasts prepared by
MACS, complement-mediated cytotoxicity, preplating and
combined preplating and MACS. Myoblast percentages
were determined by immunochemical staining for desmin.
All but complement-mediated cytotoxicity showed an
increase in the myoblast fraction after treatment. Asterisks
indicate statistical significance (p < 0.05).
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Differentiation
Myoblasts treated with MACS and/or pre-
plating fused into myotubes in five to seven days
in 1% FBS-DMEM.
DISCUSSION
The present study compared three procedures
for purifying myoblasts directly from freshly
dissociated human skeletal muscles. Immunoma-
gnetic cell sorting, MACS for example, is widely
used for blood cells but rarely applied to tissue
cell sorting. Lequerica et al.
20 reported that posi-
tive selection with MACS could be used to
increase the percentage of myoblasts in mixed
culture from 8.4% to more than 90% without
affecting viability. Therefore, we attempted to
isolate myoblasts by MACS. MACS only increased
the number of myoblasts in mixed culture from
30.0% to 41.7%, an 11.7% increment. This large
difference in results may be due to different
equipment and methods.
Preplating causes enrichment by differentiating
phenotypically distinct myoblasts and fibroblasts
based on desmin expression. Results from pre-
vious studies using various preplating techniques
have shown myoblast enrichments ranging from
78% to more than 95% of the total cell count.
17,18,21
In the present study, myoblasts, or desmin-posi-
tive cells, reached 83.1% at pp5. This was im-
proved to 92.8% with the addition of MACS. The
results demonstrate that anti-mouse immuno-
globulin (Ig)-coated beads recognize 5.1H11 on
the surface of myoblasts, and allow the cells to be
separated when subjected to a magnetic field
produced by a simple magnetic device.
Fibroblasts have a proliferate advantage over
most other cell types and tend to outgrow them,
even when the initial level of fibroblast conta-
mination is low. A variety of methods to reduce
fibroblast contamination have been reported. One
involves complement-mediated cytotoxicity using
an anti-fibroblast antibody. For example, the
monoclonal antibodies 6-19 and 1B10 fixed com-
plement have been used to remove fibroblasts
from epithelial cell culture.
22,23 This study used
antibody 1B10 to reduce or eliminate fibroblasts
in human skeletal muscle primary culture. 1B10
is specific to fibroblasts and smooth muscle
differentiated fibroblasts within the context of
vascular smooth muscle cells.
24 Our findings
reveal that the removal of fibroblasts using 1B10
and its complement was inefficient because
myoblasts were also destroyed. This suggests
that both cell types express the antigen to which
1B10 binds, and thus, myoblasts and fibroblasts
may be of a similar lineage. These results also
indicate that the anti- fibroblast antibody 1B10 is
not useful for determining fibroblast levels in
muscle tissue.
Myoblasts treated with MACS, preplating or
both methods differentiated into myotubes,
demonstrating that these isolation methods do not
affect myoblast differentiation.
There are some limitations to our experiment.
Because purifying procedures were not processed
from the same primary cell cultures, the myoblast
fractions before treatment were not equal (Fig. 1).
This is because we were not able to grow enough
primary culture cells for all the treatments from
one sample.
In conclusion, preplating in combination with
immunomagnetic purification is easy, efficient
and does not require special equipment. Neither
immunomagnetic purification nor preplating
altered myoblast function in terms of differen-
tiation into myotubes. We hope that the infor-
mation obtained from these experiments will be
Fig. 2. Characterization of the percentage of myoblasts
obtained by preplating (pp1 to pp5). The myoblast popu-
lations displayed different desmin immunoreactivities
ranging from the primary culture (21.3%) to the fifth
preplate (pp5; 83.1%). The first preplate (pp1) contained
only 29.9% desmin-positive cells, whereas the sequential
preplates contained incrementally higher levels of desmin-
positive cells.Purification of Human Myoblasts
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useful for designing strategies to maximize myo-
blast purification.
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